MENU

These 3 ASX shares just raced to 52-week highs

With the market pushing notably higher on Monday it will come as no surprise to learn that a number of shares managed to reach 52-week highs.

Three which caught my eye are summarised below. Here’s why they are flying high:

The Cynata Therapeutics Ltd (ASX: CYP) share price reached a 52-week high of 98 cents on Monday, stretching its year-to-date return to an impressive 66%. Investors have been fighting to get hold of the stem cell and regenerative medicine company’s shares following a series of positive developments. The most recent was news that the first patient with steroid-resistant acute graft-versus-host disease (GvHD) has been treated in the second cohort of Cynata’s phase 1 clinical study of its Cymerus mesenchymal stem cell product, CYP-001. The data from the first cohort of patients has been very positive. I’m a big fan of Cynata and think its technology has enormous potential.

The MGC Pharmaceuticals Ltd (ASX: MXC) share price climbed to a 52-week high of 12 cents yesterday. Investors appear to be pleased with the progress the company has made in regards to gaining its Good Manufacturing Practice (GMP) certification for its European facility. The medicinal cannabis company has been granted an interim certification, but is likely to have this upgraded to full GMP certification if the first batch of its CannEpil epilepsy product meets the required standards. Management estimates that CannEpil will generate sales of $1 million annually once it is fully approved for distribution in Australia. The company is already generating meaningful revenue from its cannabidiol-based cosmetic products, making it a bit of a rarity in the industry.

The WiseTech Global Ltd (ASX: WTC) share price continued its strong run on Monday and hit a 52-week high of $15.76. Incredibly, this means that the logistics software platform provider’s shares had rocketed over 215% in the space of 12 months. Investors appear to believe that a series of acquisitions that the company has made over the last year will add significant value in the long-term. Whilst I am a big fan of the company, I’m not a buyer at the current share price on valuation grounds.

Missed these gains? Then don't miss out on these top growth shares that have been tipped to shine in 2018.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of WiseTech Global. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.